Search Results 151-160 of 17354 for hba1c

  1. Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis - Mayo Clinic

    Uncontrolled diabetes (HbA1c ≥9%) within 60 days prior to day 1; Presence of cirrhosis on liver biopsy (fibrosis stage 4 based on the central ...

  2. Automated Insulin Delivery in Elderly with Type 1 Diabetes - Mayo Clinic

    HbA1c < 10.0% from point of care or local lab at time of screening visit. Insulin regimen involves basal/bolus insulin via insulin pump or multiple daily ...

  3. Publications - Nikola A. Baumann, Ph.D. - Mayo Clinic

    Assessing Quality Control Strategies for HbA1c Measurements From a Patient Risk Perspective. J Diabetes Sci Technol. 2018 Jul; 12 (4):786-791 Epub 2018 Feb ...

  4. Insights into IBD genetics - Mayo Clinic

    An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20538381.

  5. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis - Mayo Clinic

    Uncontrolled diabetes mellitus (HbA1c >9%). Change in diabetes medications or vitamin E within 3 months of screening. Restrictive bariatric surgery or ...

  6. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer - Mayo Clinic

    Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c) > 7%; patients with a history of transient glucose intolerance due to ...

  7. Primary biliary cholangitis - Doctors and departments - Mayo Clinic

    Primary biliary cholangitis is a type of liver disease that damages the bile ducts. Early recognition and treatment may help prevent complications.

  8. Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III - Mayo Clinic

    Poorly controlled diabetes mellitus (HbA1c >10%),; Current or within 1 month use of any form of corticosteroids,; Severe asthma that is poorly controlled on ...

  9. Phase III Copanlisib in Rituximab-refractory iNHL - Mayo Clinic

    Type I or II diabetes mellitus with HbA1c > 8.5% at Screening. Known history of human immunodeficiency virus (HIV) infection. Active clinically serious ...

  10. A Study to Evaluate the Effectiveness and Safety of Relacorilant - Mayo Clinic

    DM (fasting plasma glucose ≥ 126 mg/dL and/or 2-hour oGTT plasma glucose ≥ 200 mg/dL at 2 hours, or HbA1c ≥ 6.5%), or IGT (plasma glucose ≥ 140 mg/dL ...